Easywell Biomedicals, Inc. (TPEX: 1799)

Market Cap	7.36B
Revenue (ttm)	483.81M
Net Income (ttm)	-120.87M
Shares Out	121.87M
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	453,631
Open	60.10
Previous Close	62.70
Day's Range	60.00 - 62.30
52-Week Range	38.58 - 233.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About Easywell Biomedicals

Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea. The company al...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1799

Financial Performance

In 2023, Easywell Biomedicals's revenue was 271.63 million, an increase of 51.83% compared to the previous year's 178.90 million. Losses were -144.82 million, -10.05% less than in 2022.